Abstract Background Oral factor Xa inhibitors (FXaI) can be administered in fixed doses
without the need for routine laboratory monitoring. Anti-Xa assays can estimate …

Background The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be
inferred from their observed plasma concentrations; however, the steady-state …

Abstract Background Direct factor Xa inhibitors have demonstrated compelling anticoagulant
efficacy and/or safety profiles across multiple diverse patient populations. A specific antidote …

Background: There is no established method for monitoring the anticoagulant effects of
apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has …

Background: Oral anti-Xa inhibitors have demonstrated noninferiority to vitamin K
antagonists (VKAs) for the prevention of stroke in patients with atrial fibrillation and recurrent …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

Background Clinical situations occur where expedient assessment of the anticoagulant
activity of the direct factor Xa (FXa) inhibitors is required. Although quantitative anti‐FXa …

Introduction Direct oral anticoagulant (DOAC)–inhibiting factor Xa (FXa‐DOAC) are being
increasingly used as prophylaxis of venous thromboembolism and for prevention of stroke in …

Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …